Publication:
Editorial: Resistance to Medical Therapy in Pituitary Tumors.

Loading...
Thumbnail Image

Date

2022-01-31

Authors

Auriemma, Renata S
Gahete, Manuel D
Gatto, Federico

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Frontiers Research Foundation
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Pituitary tumors may exhibit resistance to conventional medical treatments, including somatostatin receptor (SST) ligands (SRLs) and dopamine agonists (DAs) (1, 2). Resistance to medical treatment leads to multi-modal therapies, including surgery and radiotherapy. However, treatment-resistant tumors frequently relapse after radical surgical excision. This is of crucial interest as it occurs in a considerable proportion of patients with pituitary tumors (3). Indeed, resistance to conventional treatments is nowadays considered a predictive factor of the aggressive behavior of the pituitary tumor, being associated with poor prognosis and increased mortality. Predictors of responsiveness to medical treatments are still under investigation, and there is no clear evidence for the best individualized medical therapy in patients with aggressive pituitary lesions

Description

MeSH Terms

Pituitary neoplasms
Dopamine agonists
Receptors, somatostatin
Pituitary diseases
Chronic disease
Prognosis

DeCS Terms

Agonistas de dopamina
Enfermedad crónica
Enfermedades de la hipófisis
Neoplasias hipofisarias
Pronóstico
Receptores de somatostatina

CIE Terms

Keywords

Adenomas, Dopamine receptors, Pituitary, Resistance, Somatostatin receptors, Tumors

Citation

Auriemma RS, Gahete MD, Gatto F. Editorial: Resistance to Medical Therapy in Pituitary Tumors. Front Endocrinol (Lausanne). 2022 Feb 23;13:861230